Quote this publication Share Print

ZYPREXA

-
Opinions on drugs - Posted on Mar 19 2013

Reason for request

Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.

-


Clinical Benefit

Substantial

The Actual Benefit of ZYPREXA and ZYPREXA VELOTAB in the treatment of schizophrenia remains substantial.


Clinical Added Value

moderate

ZYPREXA and ZYPREXA VELOTAB, as with all other anti-psychotics (including first generation anti-psychotics), provide a moderate Improvement in Actual Benefit (IAB III) in the treatment of schizophrenia.


Contact Us

Évaluation des médicaments

See also